Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies.Ecaterina E. Dumbrava, Haeseong Park, Jason S. Starr et al.|Journal of Clinical Oncology|2021Cited by 3
516MO Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignanciesH. Park, Ecaterina E. Dumbrava, Geoffrey I. Shapiro et al.|Annals of Oncology|2021Cited by 1